Seno Medical Instruments, Inc.

July 26, 2022 — Seno Medical’s Imagio Breast Imaging System, a revolutionary new modality in breast imaging, has ...

Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional opto-acoustic (OA/US) features provide a non-invasive approach to helping distinguish breast cancer molecular subtypes. The data were presented at the Radiological Society of North America (RSNA) 2018 annual meeting, Nov. 25-30 in Chicago, and the abstract was featured as one of three High Impact Clinical Trials selected for this special session.

Seno Medical Instruments Inc. (Seno Medical) recently reported data from their clinical study demonstrating that its Imagio opto-acoustic (OA)  breast imaging system achieved significant differentiation among prognostic subtypes of breast cancer (PSBC). These prognostic subtypes provide important information about the genes that each patient's cancer expresses. The data were presented during a poster presentation at the San Antonio Breast Cancer Symposium, Dec. 5-9 in San Antonio, Texas.

Seno Medical Instruments, Inc. announced results from two analyses of the company's European MAESTRO post-market surveillance study. The two analyses were presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) in San Antonio.

Seno Medical Instruments Inc. (Seno) announced it has completed the final phase of the company's U.S.-based PIONEER pivotal study of the Imagio breast imaging system. The system utilizes optoacoustic technology as a new tool to improve the process of diagnosing breast cancer.